Back to Top Skip to main content

Presentations to the DoD P&T Committee

Pharmacoeconomic & Budget Impact Analyses (2010-2011)

Approximate annual expenditures, all points of service

  • Aug 2011 – Contraceptives [$163M]
  • Aug 2011 – Non-steroidal anti-inflammatory drugs [$150M]
  • Aug 2011 – New drugs: Butrans, Staxyn, Edarbi, Amturnide, Cycloset
  • May 2011 – Atypical antipsychotics [$218M]
  • May 2011 – Nasal allergy drugs [$95M]
  • May 2011 – New drugs: Kombiglyze XR, Bromday, Jalyn
  • Feb 2011 – Antilipidemic-2 agents (Fibrates, omega-3 fatty acid, bile acid sequestrants) [$140M]
  • Feb 2011 – Gastrointestinal-1 agents (aminosalicylates, pancreatic enzymes, misc) [$66M]
  • Feb 2011 – New drugs: Aricept 23mg, Tekamlo, Tribenzor, blood glucose test strips
  • Nov 2010 – Non-insulin antidiabetics [$336M]
  • Nov 2010 – New drugs: Dulera, Livalo, Silenor, Exalgo, Fibricor, Natazia
  • Aug 2010 – Renin-angiotensin antihypertensive agents [$300M]
  • Aug 2010 – Topical ophthalmic anti-allergy drugs (antihistamine, mast cell stabilizers, NSAIDs) [$18M]
  • May 2010 – Antilipidemic-I products (statins, niacin, ezetimibe) [$489M]
  • May 2010 – BPH alpha blockers [$80M]
  • May 2010 – New drugs: Sumavel, Onsolis
  • Feb 2010 – Basal insulins [$80M]
  • Feb 2010 – Antihemophilic agents [$38]
  • Feb 2010 – New drugs: Edluar, Embeda, Intuniv, Twynsta, Valturna

Patterns of Use/Effect of Formulary Interventions (2010-2011)

  • Aug 2011 – Closing the loop: effects of step therapy on beneficiary behavior in 7 major drug classes
  • Aug 2011 – Indications for use: montelukast (Singulair)
  • May 2011 – Utilization of atypical antipsychotics in the MHS
  • Feb 2011 – Utilization of antidiabetics in the MHS: HbA1cs at start of oral antidiabetic therapy
  • Nov 2010 – Utilization of antidiabetics in the MHS: new users and step therapy estimates
  • Nov 2010 – Closing the loop: early results of statin step therapy; utilization of PDE-5s
  • Aug 2010 – Renin-angiotensin antihypertensives in the MHS: diagnoses, prior and concomitant use
  • Aug 2010 – Closing the loop: following up on P&T decisions

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.